# The Chemours Company (CC)

> Source: Nexqual · https://nexqual.com/CC · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, The Chemours Company (CC), nexqual.com/CC" · informational, not investment advice.

**Price:** USD 12.91 (+0.47% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 12.85 · day 12.5–13.09 · 52w 10.44–28.67 · market cap $1.94B · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $5.80B, net income -$304M (-5.2% margin), free cash flow $218M (SEC filings).
- Analysts: Hold (mean 2.80 on a 1–5 scale) (10 analysts), mean target USD 16.9 (range 14–24).
- Total return with dividends: 1Y -4.1% vs S&P 500 +18.1%; 5Y -50.6% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD 0.26, revenue estimate $1.53B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $6.34B | $6.83B | $6.08B | $5.78B | $5.81B | $5.80B |
| Gross profit | $1.38B | $1.62B | $1.30B | $1.14B | $902M | — |
| Net income | $608M | $578M | -$253M | $69.0M | -$386M | -$304M |
| EPS (diluted) | $3.60 | $3.65 | -$1.70 | $0.46 | -$2.57 | — |
| Free cash flow | $537M | $448M | $186M | -$993M | $51.0M | $218M |
| Gross margin | 21.8% | 23.7% | 21.4% | 19.8% | 15.5% | — |
| Net margin | 9.6% | 8.5% | -4.2% | 1.2% | -6.6% | -5.2% |
| Revenue growth | +27.7% | +7.7% | -11.0% | -4.9% | +0.4% | — |
| Cash + short-term investments | $1.45B | $1.10B | $1.20B | $713M | $670M | — |
| Total debt | $3.75B | $3.63B | $4.04B | $4.11B | $4.14B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 0.3x · EV/Sales 0.9x · P/FCF 8.9x · FCF yield 11.22% · Earnings yield -15.65% · Dividend yield (paid, TTM) 2.78% · Net debt $3.20B · EV $5.14B
P/E at fiscal year-ends: Dec 2024 36.8x.

## Analysts
Consensus Hold (mean 2.80 on a 1–5 scale), 10 analysts; mean target USD 16.9 (low 14, high 24).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Mizuho | Downgrade | Outperform → Neutral | $18 → $15 |
| 2026-10-13 | Barclays | Initiated | Equal-Weight | $16 |
| 2026-10-05 | UBS | Target lowered | Neutral | $18 → $16 |
| 2026-09-30 | Mizuho | Target lowered | Outperform | $20 → $18 |
| 2026-08-13 | JP Morgan | Target lowered | Neutral | $22 → $15 |
| 2026-08-13 | BMO Capital | Target lowered | Outperform | $26 → $18 |
| 2026-08-10 | UBS | Downgrade | Buy → Neutral | $29 → $18 |
| 2026-08-06 | RBC Capital | Target lowered | Outperform | $26 → $22 |
| 2026-08-06 | Truist Securities | Target lowered | Buy | $30 → $24 |
| 2026-07-01 | Mizuho | Target lowered | Outperform | $30 → $25 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -4.1% | -50.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -4.1% | -13.1% |
| Volatility (annualized) | 62.1% | 56.2% |
| Max drawdown | -53.6% (May 2026→Oct 2026) | -74.1% (May 2022→May 2025) |

## Peers (Specialty Chemicals)
CLMT (Calumet, Inc) USD 58.24 -0.60% · BCPC (Balchem Corporation) USD 170.53 +0.48% · SXT (Sensient Technologies Corporati) USD 133.42 +0.66% · AXTA (Axalta Coating Systems Ltd.) USD 33.73 +0.60% · EMN (Eastman Chemical Company) USD 63.87 +1.38% · WLK (Westlake Corporation) USD 63.61 +2.83%

## More
Full page: https://nexqual.com/CC · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt